Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2009

Biofield Gets Global Rights to ValiRx’ Diagnostic Products

  • Biofield gained exclusive, worldwide distribution rights outside of Belgium for ValiRx' HPV diagnostic for cervical cancer as well as its HyperGenomics and Nucleosomics cancer diagnostic platforms.

    HyperGenomics is a method for the detection and identification of hypersensitive sites in cells. ValiRx is developing differential diagnostic and prognostic products as well as tests for personalized medicine using this technology.

    Nucleosomics is a platform for noninvasive blood tests for early cancer diagnosis based on epigenetic signal changes associated with malignancy. ELISA tests for global histone modifications expressed in cell-free nucleosomes in blood that are characteristic of cancers are currently under development. ValiRx expects to launch early Nucleosomics products for research use in 2009. Diagnostic products regulated by EMEA and the FDA will follow, the firm adds. Early disease focus is in lung, pancreatic, and colon cancer.

    Initially, Biofield was focused on securing FDA approval to distribute its Biofield Diagnostic System for the early detection of breast cancer. It has, however, reoriented itself to offering noninvasive and cost-effective technologies to foreign markets.

    Currently, the firm plans on distributing its entire diagnostic product portfolio in China (including Hong King, Taiwan, and Macau), India, The Philippines, Indonesia, Malaysia, Singapore, Vietnam, Mexico, Latin America, and Europe.

    Recently it was reported Biofield acquired exclusive, worldwide distribution rights for NeuroMed's oral herpes device. The company has been preparing to begin marketing the product at its new Bangalore, India, office. The company expects to fully begin marketing its product within the next 30 days.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »